{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T22:15:58Z","timestamp":1789942558103,"version":"4.0.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T00:00:00Z","timestamp":1551657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100011264","name":"FP7 People: Marie-Curie Actions","doi-asserted-by":"publisher","award":["RISE-2017-CROSS NEUROD"],"award-info":[{"award-number":["RISE-2017-CROSS NEUROD"]}],"id":[{"id":"10.13039\/100011264","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s12035-019-1533-2","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T05:03:56Z","timestamp":1551675836000},"page":"6460-6471","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Disease Modeling and Therapeutic Strategies in CMT2A: State of the Art"],"prefix":"10.1007","volume":"56","author":[{"given":"Kordelia","family":"Barbullushi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Abati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nereo","family":"Bresolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo P.","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,4]]},"reference":[{"issue":"5","key":"1533_CR1","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/ng1341","volume":"36","author":"S Z\u00fcchner","year":"2004","unstructured":"Z\u00fcchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, Zappia M, Nelis E et al (2004) Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 36(5):449\u2013451","journal-title":"Nat Genet"},{"issue":"1\u20132","key":"1533_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jns.2015.05.033","volume":"356","author":"G Stuppia","year":"2015","unstructured":"Stuppia G, Rizzo F, Riboldi G, Del Bo R, Nizzardo M, Simone C et al (2015) MFN2-related neuropathies: clinical features, molecular pathogenesis and therapeutic perspectives. J Neurol Sci 356(1\u20132):7\u201318. Available from:\n                           \n                    https:\/\/doi.org\/10.1016\/j.jns.2015.05.033","journal-title":"J Neurol Sci"},{"issue":"1","key":"1533_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1468-1331.2010.03037.x","volume":"18","author":"GJ Braathen","year":"2011","unstructured":"Braathen GJ, Sand JC, Lobato A, H\u00f8yer H, Russell MB (2011) Genetic epidemiology of Charcot-Marie-Tooth in the general population. Eur J Neurol 18(1):39\u201348","journal-title":"Eur J Neurol"},{"issue":"3","key":"1533_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000443706","volume":"46","author":"LCLS Barreto","year":"2016","unstructured":"Barreto LCLS, Oliveira FS, Nunes PS, De Fran\u00e7a Costa IMP, Garcez CA, Goes GM et al (2016) Epidemiologic study of Charcot-Marie-Tooth disease: a systematic review. Neuroepidemiology 46(3):157\u2013165","journal-title":"Neuroepidemiology"},{"issue":"3","key":"1533_CR5","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s12017-014-8307-9","volume":"16","author":"G Bergamin","year":"2014","unstructured":"Bergamin G, Boaretto F, Briani C, Pegoraro E, Cacciavillani M, Martinuzzi A, Muglia M, Vettori A et al (2014) Mutation analysis of MFN2, GJB1, MPZ and PMP22 in Italian patients with axonal Charcot-Marie-Tooth disease. NeuroMolecular Med 16(3):540\u2013550","journal-title":"NeuroMolecular Med"},{"issue":"8","key":"1533_CR6","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1093\/brain\/awl126","volume":"129","author":"K Verhoeven","year":"2006","unstructured":"Verhoeven K, Claeys KG, Z\u00fcchner S, Schr\u00f6der JM, Weis J, Ceuterick C et al (2006) MFN2 mutation distribution and genotype\/phenotype correlation in Charcot-Marie-Tooth type 2. Brain 129(8):2093\u20132102","journal-title":"Brain"},{"issue":"20","key":"1533_CR7","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1212\/WNL.0b013e31821a441e","volume":"76","author":"SME Feely","year":"2011","unstructured":"Feely SME, Laura M, Siskind CE, Sottile S, Davis M, Gibbons VS, Reilly MM, Shy ME (2011) MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology 76(20):1690\u20131696","journal-title":"Neurology"},{"issue":"4","key":"1533_CR8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/jns.12145","volume":"20","author":"G Piscosquito","year":"2015","unstructured":"Piscosquito G, Saveri P, Magri S, Ciano C, Di Bella D, Milani M et al (2015) Mutational mechanisms in MFN2 -related neuropathy: compound heterozygosity for recessive and semidominant mutations. J Peripher Nerv Syst 20(4):380\u2013386","journal-title":"J Peripher Nerv Syst"},{"key":"1533_CR9","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1212\/01.wnl.0000311275.89032.22","volume":"70","author":"GA Nicholson","year":"2008","unstructured":"Nicholson GA, Magdelaine C, Zhu D, Grew S, Ryan MM, Sturtz F, Vallat JM, Ouvrier RA (2008) Severe early-onset axonal neuropathy with homozygous and compound heterozygous MFN2 mutations. Neurology 70:1678\u20131681","journal-title":"Neurology"},{"key":"1533_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1212\/WNL.0b013e3182242d4d","volume":"77","author":"JM Polke","year":"2011","unstructured":"Polke JM, Laura M, Pareyson D, Taroni F, Milani M, Bergamin G, Gibbons VS, Houlden H et al (2011) Recessive axonal Charcot-Marie-Tooth disease due to compound heterozygous mitofusin 2 mutations. Neurology 77:168\u2013173","journal-title":"Neurology"},{"issue":"6","key":"1533_CR11","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/ajmg.a.37611","volume":"170","author":"CA Tan","year":"2016","unstructured":"Tan CA, Rabideau M, Blevins A, Westbrook MJ, Ekstein T, Nykamp K, Deucher A, Harper A et al (2016) Autosomal recessive MFN2-related Charcot-Marie-Tooth disease with diaphragmatic weakness: case report and literature review. Am J Med Genet 170(6):1580\u20131584","journal-title":"Am J Med Genet"},{"key":"1533_CR12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/01.wnl.0000171345.62270.29","volume":"65","author":"D Zhu","year":"2005","unstructured":"Zhu D, Kennerson ML, Walizada G, Vance JM, Nicholson GA (2005) Charcot-Marie-Tooth with pyramidal signs is genetically heterogeneous: families with and without MFN2 mutations. Neurology 65:496\u2013497","journal-title":"Neurology"},{"issue":"2","key":"1533_CR13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ana.20797","volume":"59","author":"S Z\u00fcchner","year":"2006","unstructured":"Z\u00fcchner S, De Jonghe P, Jordanova A, Claeys KG, Guergueltcheva V, Cherninkova S et al (2006) Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2. Ann Neurol 59(2):276\u2013281","journal-title":"Ann Neurol"},{"key":"1533_CR14","doi-asserted-by":"publisher","unstructured":"Filadi R, Pendin D, Pizzo P (2018) Mitofusin 2: from functions to disease. Cell Death Dis 9(3). Available from: \n                    https:\/\/doi.org\/10.1038\/s41419-017-0023-6","DOI":"10.1038\/s41419-017-0023-6"},{"key":"1533_CR15","unstructured":"Chandhok G, Lazarou M, Neumann B (2017) Structure, function, and regulation of mitofusin-2 in health and disease. Biol Rev 61"},{"key":"1533_CR16","doi-asserted-by":"publisher","unstructured":"El Fissi N, Rojo M, Aouane A, Karatas E, Poliacikova G, David C, Royet J, Rival T (2018) Mitofusin gain and loss of function drive pathogenesis in Drosophila models of CMT2A neuropathy. EMBO Rep 19:e45241. Available from: \n                    https:\/\/doi.org\/10.15252\/embr.201745241","DOI":"10.15252\/embr.201745241"},{"key":"1533_CR17","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1001\/jamaneurol.2014.629","volume":"71","author":"F Bombelli","year":"2014","unstructured":"Bombelli F, Stojkovic T, Dubourg O, Echaniz-Laguna A, Tardieu S, Larcher K, Amati-Bonneau P, Latour P et al (2014) Charcot-Marie-Tooth disease type 2A from typical to rare phenotypic and genotypic features. JAMA Neurol 71:1036\u20131042","journal-title":"JAMA Neurol"},{"issue":"2","key":"1533_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1212\/01.wnl.0000168898.76071.70","volume":"65","author":"VH Lawson","year":"2005","unstructured":"Lawson VH, Graham BV, Flanigan KM (2005) Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. Neurology 65(2):197\u2013204","journal-title":"Neurology"},{"issue":"4","key":"1533_CR19","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663\u2013676","journal-title":"Cell"},{"key":"1533_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.expneurol.2014.10.005","volume":"263","author":"MA Saporta","year":"2015","unstructured":"Saporta MA, Dang V, Volfson D, Zou B, Xie XS, Adebola A et al (2015) Axonal Charcot-Marie-Tooth disease patient-derived motor neurons demonstrate disease-specific phenotypes including abnormal electrophysiological properties. Exp Neurol 263:190\u2013199","journal-title":"Exp Neurol"},{"issue":"19","key":"1533_CR21","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1093\/hmg\/ddw258","volume":"25","author":"F Rizzo","year":"2016","unstructured":"Rizzo F, Ronchi D, Salani S, Nizzardo M, Fortunato F, Bordoni A, Stuppia G, del Bo R et al (2016) Selective mitochondrial depletion, apoptosis resistance, and increased mitophagy in human Charcot-Marie-Tooth 2A motor neurons. Hum Mol Genet 25(19):4266\u20134281","journal-title":"Hum Mol Genet"},{"issue":"5","key":"1533_CR22","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/brain\/awq082","volume":"133","author":"R Cartoni","year":"2010","unstructured":"Cartoni R, Arnaud E, M\u00e9dard JJ, Poirot O, Courvoisier DS, Chrast R, Martinou JC (2010) Expression of mitofusin 2R94Q in a transgenic mouse leads to Charcot-Marie-Tooth neuropathy type 2A. Brain. 133(5):1460\u20131469","journal-title":"Brain."},{"issue":"12","key":"1533_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1371\/journal.pone.0167573","volume":"11","author":"P Bannerman","year":"2016","unstructured":"Bannerman P, Burns T, Xu J, Miers L, Pleasure D (2016) Mice hemizygous for a pathogenic mitofusin- 2 allele exhibit hind limb\/foot gait deficits and phenotypic perturbations in nerve and muscle. PLoS One 11(12):17\u201322","journal-title":"PLoS One"},{"issue":"2","key":"1533_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1083\/jcb.200211046","volume":"160","author":"H Chen","year":"2003","unstructured":"Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC (2003) Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 160(2):189\u2013200","journal-title":"J Cell Biol"},{"issue":"12","key":"1533_CR25","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.1523\/JNEUROSCI.6248-09.2010","volume":"30","author":"A Misko","year":"2010","unstructured":"Misko A, Jiang S, Wegorzewska I, Milbrandt J, Baloh RH (2010) Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro\/Milton complex. J Neurosci 30(12):4232\u20134240. Available from: \n                    https:\/\/doi.org\/10.1523\/JNEUROSCI.6248-09.2010","journal-title":"J Neurosci"},{"issue":"12","key":"1533_CR26","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1523\/JNEUROSCI.6338-11.2012","volume":"32","author":"AL Misko","year":"2012","unstructured":"Misko AL, Sasaki Y, Tuck E, Milbrandt J, Baloh RH (2012) Mitofusin2 mutations disrupt axonal mitochondrial positioning and promote axon degeneration. J Neurosci 32(12):4145\u20134155. Available from:\n                           \n                    https:\/\/doi.org\/10.1523\/JNEUROSCI.6338-11.2012","journal-title":"J Neurosci"},{"key":"1533_CR27","doi-asserted-by":"publisher","unstructured":"Bhandari P, Song M, Chen Y, Burelle Y, Dorn GW II (2014) Mitochondrial contagion induced by parkin deficiency in drosophila hearts and its containment by suppressing mitofusin. Circulation Research 114(2):257\u2013265. Available from: \n                    https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.302734","DOI":"10.1161\/CIRCRESAHA.114.302734"},{"issue":"1","key":"1533_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.nmd.2010.09.002","volume":"21","author":"A Vettori","year":"2011","unstructured":"Vettori A, Bergamin G, Moro E, Vazza G, Polo G, Tiso N, Argenton F, Mostacciuolo ML (2011) Developmental defects and neuromuscular alterations due to mitofusin 2 gene (MFN2) silencing in zebrafish: a new model for Charcot-Marie-Tooth type 2A neuropathy. Neuromuscul Disord 21(1):58\u201367. Available from: \n                    https:\/\/doi.org\/10.1016\/j.nmd.2010.09.002","journal-title":"Neuromuscul Disord"},{"key":"1533_CR29","doi-asserted-by":"crossref","unstructured":"Chapman AL, Bennett EJ, Ramesh TM, De Vos KJ, Grierson AJ (2013) Axonal transport defects in a mitofusin 2 loss of function model of Charcot-Marie-Tooth disease in zebrafish. PLoS One 8(6)","DOI":"10.1371\/journal.pone.0067276"},{"key":"1533_CR30","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/WCO.0000000000000474","volume":"30","author":"D Pareyson","year":"2017","unstructured":"Pareyson D, Saveri P, Pisciotta C (2017) New developments in Charcot\u2013Marie\u2013Tooth neuropathy and related diseases. Curr Opin Neurol 30:471\u2013480","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"1533_CR31","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1523\/JNEUROSCI.09-02-00625.1989","volume":"9","author":"CF Eldridge","year":"1989","unstructured":"Eldridge CF, Bunge MB, Bunge RP (1989) Differentiation of axon-related Schwann cells in vitro: II. Control of myelin formation by basal lamina. J Neurosci 9(2):625\u2013638","journal-title":"J Neurosci"},{"key":"1533_CR32","doi-asserted-by":"crossref","unstructured":"Gess B, Baets J, De Jonghe P, Reilly MM, Pareyson D, Young P (2015) Ascorbic acid for the treatment of Charcot-Marie-Tooth disease ( review ). Cochrane Database Syst Rev (12)","DOI":"10.1002\/14651858.CD011952"},{"issue":"12","key":"1533_CR33","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/nm957","volume":"9","author":"MW Sereda","year":"2003","unstructured":"Sereda MW, Meyer Zu H\u00f6rste G, Suter U, Uzma N, Nave KA (2003) Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 9(12):1533\u20131537","journal-title":"Nat Med"},{"key":"1533_CR34","doi-asserted-by":"publisher","unstructured":"Chahbouni M, L\u00f2pez MS, Molina-Carballo A, Haro D, Mu\u00f1oz-Hoyos A, Fern\u00e0ndez-Ortis M, Guerra-Librero A, Acuna-Castroviejo D (2017) Melatonin treatment reduces oxidative damage and normalizes plasma pro-inflammatory cytokines in patients suffering from Charcot-Marie-Tooth neuropathy: a pilot study in three children. Molecules 22(1728):1-14. Available from: \n                    https:\/\/doi.org\/10.3390\/molecules22101728","DOI":"10.3390\/molecules22101728"},{"issue":"5","key":"1533_CR35","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/mus.20621","volume":"34","author":"CA Smith","year":"2006","unstructured":"Smith CA, Chetlin RD, Gutmann L, Yeater RA, Alway SE (2006) Effects of exercise and creatine on myosin heavy chain isoform composition in patients with Charcot-Marie-Tooth disease. Muscle Nerve 34(5):586\u2013594","journal-title":"Muscle Nerve"},{"issue":"7631","key":"1533_CR36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nature20156","volume":"540","author":"A Franco","year":"2016","unstructured":"Franco A, Kitsis RN, Fleischer JA, Gavathiotis E, Kornfeld OS, Gong G, Biris N, Benz A et al (2016) Correcting mitochondrial fusion by manipulating mitofusin conformations. Nature 540(7631):74\u201379. Available from:\n                           \n                    https:\/\/doi.org\/10.1038\/nature20156","journal-title":"Nature"},{"issue":"6386","key":"1533_CR37","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1126\/science.aao1785","volume":"360","author":"AG Rocha","year":"2018","unstructured":"Rocha AG, Franco A, Krezel AM, Rumsey JM, Alberti JM, Knight WC et al (2018) MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A. Science (80- ) 360(6386):336\u2013341","journal-title":"Science (80- )"},{"issue":"18","key":"1533_CR38","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377(18):1713\u20131722. Available from:\n                           \n                    https:\/\/doi.org\/10.1056\/NEJMoa1706198","journal-title":"N Engl J Med"},{"issue":"2","key":"1533_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/j.1471-4159.2004.02860.x","volume":"92","author":"GX Xu","year":"2005","unstructured":"Xu GX, Zhou H, Zhou S, Yu Y, Wu R, Xu Z (2005) An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase. J Neurochem 92(2):362\u2013367","journal-title":"J Neurochem"},{"key":"1533_CR40","doi-asserted-by":"publisher","unstructured":"Rinaldi C, Wood MJA (2017) Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol. Available from: \n                    https:\/\/doi.org\/10.1038\/nrneurol.2017.148\n                    \n                  .","DOI":"10.1038\/nrneurol.2017.148"},{"issue":"4","key":"1533_CR41","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.nurt.2008.07.001","volume":"5","author":"DN Herrmann","year":"2008","unstructured":"Herrmann DN (2008) Experimental therapeutics in hereditary neuropathies: the past, the present, and the future. Neurotherapeutics. 5(4):507\u2013515","journal-title":"Neurotherapeutics."},{"issue":"4","key":"1533_CR42","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy SM (2017) Nusinersen: first global approval. Drugs. 77(4):473\u2013479","journal-title":"Drugs."},{"key":"1533_CR43","doi-asserted-by":"crossref","unstructured":"Voelker R (2016) First DMD drug gains approval. JAMA 316(17):1756","DOI":"10.1001\/jama.2016.15537"},{"issue":"2","key":"1533_CR44","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.gene.2013.12.019","volume":"538","author":"Y Deng","year":"2014","unstructured":"Deng Y, Wang CC, Choy KW, Du Q, Chen J, Wang Q et al (2014) Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene 538(2):217\u2013227","journal-title":"Gene"},{"issue":"2\u20133","key":"1533_CR45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.addr.2007.03.005","volume":"59","author":"L Aagaard","year":"2007","unstructured":"Aagaard L, Rossi JJ (2007) RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 59(2\u20133):75\u201386","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"1533_CR46","first-page":"1","volume":"4","author":"JKW Lam","year":"2015","unstructured":"Lam JKW, Chow MYT, Zhang Y, Leung SWS (2015) siRNA versus miRNA as therapeutics for gene silencing. Mol Ther - Nucleic Acids 4(9):1\u201320","journal-title":"Mol Ther - Nucleic Acids"},{"key":"1533_CR47","doi-asserted-by":"publisher","unstructured":"Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F (2013) Multiplex genome engineering using CRISPR\/Cas systems. Science 339(6121):819-823. Available from: \n                    https:\/\/doi.org\/10.1126\/science.1231143","DOI":"10.1126\/science.1231143"},{"key":"1533_CR48","doi-asserted-by":"publisher","unstructured":"Zhan T, Rindtorff N, Betge J, Ebert MP, Boutros M (2018) CRISPR\/Cas9 for cancer research and therapy. Semin Cancer Biol. Available from: \n                    https:\/\/doi.org\/10.1016\/j.semcancer.2018.04.001","DOI":"10.1016\/j.semcancer.2018.04.001"},{"key":"1533_CR49","doi-asserted-by":"publisher","unstructured":"Zhang XH, Tee LY, Wang XG, Huang QS, Yang SH (2015) Off-target effects in CRISPR\/Cas9-mediated genome engineering. Mol Ther - Nucleic Acids 4(11):e264. Available from: \n                    https:\/\/doi.org\/10.1038\/mtna.2015.37","DOI":"10.1038\/mtna.2015.37"},{"issue":"7","key":"1533_CR50","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.cell.2017.10.025","volume":"171","author":"HK Liao","year":"2017","unstructured":"Liao HK, Hatanaka F, Araoka T, Reddy P, Wu MZ, Sui Y et al (2017) In vivo target gene activation via CRISPR\/Cas9-mediated trans-epigenetic modulation. Cell 171(7):1495\u20131507.e15","journal-title":"Cell"},{"key":"1533_CR51","doi-asserted-by":"publisher","unstructured":"Baylis F, McLeod M (2017) First-in-human phase 1 CRISPR gene editing cancer trials: are we ready? Curr Gene Ther 17:309\u2013319. Available from: \n                    https:\/\/doi.org\/10.2174\/1566523217666171121165935","DOI":"10.2174\/1566523217666171121165935"},{"issue":"1","key":"1533_CR52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11481-016-9724-3","volume":"12","author":"CR Joshi","year":"2017","unstructured":"Joshi CR, Labhasetwar V, Ghorpade A (2017) Destination brain: The past, present, and future of therapeutic gene delivery. J NeuroImmune Pharmacol 12(1):51\u201383","journal-title":"J NeuroImmune Pharmacol"},{"key":"1533_CR53","doi-asserted-by":"publisher","unstructured":"DeVos SL, Miller T (2013) Direct intraventricular delivery of drugs to the rodent central nervous system. J Vis Exp.75:e50326. Available from: \n                    https:\/\/doi.org\/10.3791\/50326","DOI":"10.3791\/50326"},{"key":"1533_CR54","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.neuropharm.2012.03.004","volume":"69","author":"MS Weinberg","year":"2013","unstructured":"Weinberg MS, Samulski RJ, McCown TJ (2013) Adeno-associated virus (AAV) gene therapy for neurological disease. Neuropharmacology 69:82\u201388. Available from:\n                           \n                    https:\/\/doi.org\/10.1016\/j.neuropharm.2012.03.004","journal-title":"Neuropharmacology"},{"issue":"3","key":"1533_CR55","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ymthe.2005.10.008","volume":"13","author":"RL Klein","year":"2006","unstructured":"Klein RL, Dayton RD, Leidenheimer NJ, Jansen K, Golde TE, Zweig RM (2006) Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther 13(3):517\u2013527. Available from:\n                           \n                    https:\/\/doi.org\/10.1016\/j.ymthe.2005.10.008","journal-title":"Mol Ther"},{"issue":"3","key":"1533_CR56","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/mt.2009.286","volume":"18","author":"EA Markakis","year":"2010","unstructured":"Markakis EA, Vives KP, Bober J, Leichtle S, Leranth C, Beecham J, Elsworth JD, Roth RH et al (2010) Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. Mol Ther 18(3):588\u2013593. Available from:\n                           \n                    https:\/\/doi.org\/10.1038\/mt.2009.286","journal-title":"Mol Ther"},{"key":"1533_CR57","doi-asserted-by":"crossref","unstructured":"Hadaczek P, Forsayeth J, Mirek H, Munson K, Bringas J, Pivirotto P, McBride JL, Davidson BL, Bankiewicz KS (2009) Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther 20:225\u2013237","DOI":"10.1089\/hum.2008.151"},{"issue":"1","key":"1533_CR58","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27(1):59\u201365","journal-title":"Nat Biotechnol"},{"key":"1533_CR59","doi-asserted-by":"publisher","unstructured":"Foust KD, Salazar DL, Likhite S, Ferraiuolo L, Ditsworth D, Ilieva H, Meyer K, Schmelzer L, Braun L, Cleveland DW, Kaspar BK (2013) Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Molecular Therapy 21(12):2148\u20132159. Available from: \n                    https:\/\/doi.org\/10.1038\/mt.2013.211","DOI":"10.1038\/mt.2013.211"},{"issue":"3","key":"1533_CR60","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/mt.2014.210","volume":"23","author":"K Meyer","year":"2015","unstructured":"Meyer K, Ferraiuolo L, Schmelzer L, Braun L, Mcgovern V, Likhite S et al (2015) Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose\u2013response study in mice and nonhuman primates. Mol Ther 23(3):477\u2013487. Available from:\n                           \n                    https:\/\/doi.org\/10.1038\/mt.2014.210","journal-title":"Mol Ther"},{"key":"1533_CR61","doi-asserted-by":"publisher","first-page":"16046","DOI":"10.1038\/mtm.2016.46","volume":"3","author":"A Miyanohara","year":"2016","unstructured":"Miyanohara A, Kamizato K, Juhas S, Juhasova J, Navarro M, Marsala S et al (2016) Potent spinal parenchymal AAV9-mediated gene delivery by subpial injection in adult rats and pigs. Mol Ther - Methods Clin Dev 3:16046. Available from:\n                           \n                    https:\/\/doi.org\/10.1038\/mtm.2016.46","journal-title":"Mol Ther - Methods Clin Dev"},{"issue":"1","key":"1533_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.joco.2018.01.006","volume":"30","author":"H Ameri","year":"2018","unstructured":"Ameri H (2018) Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation. J Curr Ophthalmol 30(1):1\u20132. Available from: \n                    https:\/\/doi.org\/10.1016\/j.joco.2018.01.006","journal-title":"J Curr Ophthalmol"},{"issue":"2","key":"1533_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.1500078","volume":"1","author":"M Nizzardo","year":"2015","unstructured":"Nizzardo M, Simone C, Rizzo F, Salani S, Dametti S, Rinchetti P et al (2015) Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model. Sci Adv 1(2):1\u201310","journal-title":"Sci Adv"},{"issue":"4","key":"1533_CR64","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/mus.24321","volume":"50","author":"BL Johnson-Kerner","year":"2014","unstructured":"Johnson-Kerner BL, Roth L, Greene JP, Wichterle H, Sproule DM (2014) Giant axonal neuropathy: An updated perspective on its pathology and pathogenesis. Muscle Nerve 50(4):467\u2013476","journal-title":"Muscle Nerve"},{"issue":"5","key":"1533_CR65","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1212\/01.WNL.0000171978.70849.c5","volume":"65","author":"Z Sahenk","year":"2005","unstructured":"Sahenk Z, Nagaraja HN, McCracken BS, King WM, Freimer ML, Cedarbaum JM et al (2005) NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology. 65(5):681\u2013689","journal-title":"Neurology."},{"issue":"11","key":"1533_CR66","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/3473","volume":"16","author":"JD Flax","year":"1998","unstructured":"Flax JD, Aurora S, Yang C, Simonin C, Wills AM, Billinghurst LL, Jendoubi M, Sidman RL et al (1998) Engraftable human neural stem cells respond to development cues, replace neurons, and express foreign genes. Nat Biotechnol 16(11):1033\u20131039","journal-title":"Nat Biotechnol"},{"issue":"2","key":"1533_CR67","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/hmg\/ddi446","volume":"15","author":"S Corti","year":"2006","unstructured":"Corti S, Locatelli F, Papadimitriou D, Donadoni C, Del Bo R, Crimi M et al (2006) Transplanted ALDHhiSSCloneural stem cells generate motor neurons and delay disease progression of nmd mice, an animal model of SMARD1. Hum Mol Genet 15(2):167\u2013187","journal-title":"Hum Mol Genet"},{"issue":"15","key":"1533_CR68","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1093\/hmg\/ddw163","volume":"25","author":"M Nizzardo","year":"2015","unstructured":"Nizzardo M, Bucchia M, Ramirez A, Trombetta E, Bresolin N, Comi GP et al (2015) iPSC-derived LewisX+CXCR4+\u03b21-integrin+ neural stem cells improve the amyotrophic lateral sclerosis phenotype by preserving motor neurons and muscle innervation in human and rodent models. Hum Mol Genet 25(15):3152\u20133163","journal-title":"Hum Mol Genet"},{"issue":"6","key":"1533_CR69","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.stem.2013.04.003","volume":"12","author":"YM Yang","year":"2013","unstructured":"Yang YM, Gupta SK, Kim KJ, Powers BE, Cerqueira A, Wainger BJ, Ngo HD, Rosowski KA et al (2013) A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell 12(6):713\u2013726. Available from:\n                           \n                    https:\/\/doi.org\/10.1016\/j.stem.2013.04.003","journal-title":"Cell Stem Cell"},{"issue":"2","key":"1533_CR70","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.stemcr.2014.06.004","volume":"3","author":"C Simone","year":"2014","unstructured":"Simone C, Nizzardo M, Rizzo F, Ruggieri M, Riboldi G, Salani S, Bucchia M, Bresolin N et al (2014) IPSC-derived neural stem cells act via kinase inhibition to exert neuroprotective effects in spinal muscular atrophy with respiratory distress type 1. Stem Cell Reports 3(2):297\u2013311. Available from:\n                           \n                    https:\/\/doi.org\/10.1016\/j.stemcr.2014.06.004","journal-title":"Stem Cell Reports"},{"issue":"1\u20132","key":"1533_CR71","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cellimm.2008.06.003","volume":"253","author":"A Leal","year":"2008","unstructured":"Leal A, Ichim TE, Marleau AM, Lara F, Kaushal S, Riordan NH (2008) Immune effects of mesenchymal stem cells: Implications for Charcot-Marie-Tooth disease. Cell Immunol 253(1\u20132):11\u201315","journal-title":"Cell Immunol"},{"issue":"10","key":"1533_CR72","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrd4738","volume":"14","author":"EA Kimbrel","year":"2015","unstructured":"Kimbrel EA, Lanza R (2015) Current status of pluripotent stem cells: moving the first therapies to the clinic. Nat Rev Drug Discov 14(10):681\u2013692. Available from:\n                           \n                    https:\/\/doi.org\/10.1038\/nrd4738","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1533_CR73","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrd.2016.245","volume":"16","author":"Y Shi","year":"2017","unstructured":"Shi Y, Inoue H, Wu JC, Yamanaka S (2017) Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov 16(2):115\u2013130. Available from:\n                           \n                    https:\/\/doi.org\/10.1038\/nrd.2016.245","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1533_CR74","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1529-8027.2011.00350.x","volume":"16","author":"SM Murphy","year":"2011","unstructured":"Murphy SM, Herrmann DN, McDermott MP, Scherer SS, Shy ME, Reilly MM et al (2011) Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst 16(3):191\u2013198","journal-title":"J Peripher Nerv Syst"},{"issue":"3","key":"1533_CR75","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/ana.25009","volume":"82","author":"KMD Cornett","year":"2017","unstructured":"Cornett KMD, Menezes MP, Shy RR, Moroni I, Pagliano E, Pareyson D, Estilow T, Yum SW et al (2017) Natural history of Charcot-Marie-Tooth disease during childhood. Ann Neurol 82(3):353\u2013359","journal-title":"Ann Neurol"},{"issue":"11","key":"1533_CR76","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1136\/jnnp-2017-315721","volume":"88","author":"R Fledrich","year":"2017","unstructured":"Fledrich R, Mannil M, Leha A, Ehbrecht C, Solari A, Pelayo-Negro AL, Berciano J, Schlotter-Weigel B et al (2017) Biomarkers predict outcome in Charcot-Marie-Tooth disease 1A. J Neurol Neurosurg Psychiatry 88(11):941\u2013952","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-019-1533-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-019-1533-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-019-1533-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T19:08:21Z","timestamp":1583176101000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-019-1533-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,4]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1533"],"URL":"https:\/\/doi.org\/10.1007\/s12035-019-1533-2","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,4]]},"assertion":[{"value":"13 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}